Bart Winters

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. ncbi Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data
    Bart Winters
    Virco BVBA, Mechelen, Belgium
    J Acquir Immune Defic Syndr 48:26-34. 2008
  2. ncbi A combined genotypic and phenotypic human immunodeficiency virus type 1 recombinant virus assay for the reverse transcriptase and integrase genes
    Kurt Van Baelen
    Virco BVBA, Generaal De Wittelaan L11 B3, Mechelen, Belgium
    J Virol Methods 161:231-9. 2009
  3. ncbi Clinical cut-offs for HIV-1 phenotypic resistance estimates: update based on recent pivotal clinical trial data and a revised approach to viral mixtures
    Bart Winters
    Virco BVBA, Mechelen, Belgium
    J Virol Methods 162:101-8. 2009
  4. ncbi A synthetic HIV-1 subtype C backbone generates comparable PR and RT resistance profiles to a subtype B backbone in a recombinant virus assay
    David Nauwelaers
    Virco BVBA, Beerse, Belgium
    PLoS ONE 6:e19643. 2011
  5. ncbi The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine
    Michael Sproat
    St Stephens Centre, Chelsea and Westminster Healthcare NHS Trust, London, UK
    Antivir Ther 10:357-61. 2005
  6. ncbi Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study)
    Isabelle Pellegrin
    Department of Virology, Bordeaux University Hospital, Bordeaux, France
    Antivir Ther 13:271-9. 2008

Collaborators

Detail Information

Publications6

  1. ncbi Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data
    Bart Winters
    Virco BVBA, Mechelen, Belgium
    J Acquir Immune Defic Syndr 48:26-34. 2008
    ..Clinically relevant cutoffs are needed for the interpretation of HIV-1 phenotypic resistance estimates as predicted by "virtual" phenotype HIV resistance analysis...
  2. ncbi A combined genotypic and phenotypic human immunodeficiency virus type 1 recombinant virus assay for the reverse transcriptase and integrase genes
    Kurt Van Baelen
    Virco BVBA, Generaal De Wittelaan L11 B3, Mechelen, Belgium
    J Virol Methods 161:231-9. 2009
    ..1 and 2.0 for raltegravir and elvitegravir, respectively. In summary, a genotypic and phenotypic integrase resistance assay was validated successfully for accuracy, reproducibility, analytical and clinical sensitivity, and dynamic range...
  3. ncbi Clinical cut-offs for HIV-1 phenotypic resistance estimates: update based on recent pivotal clinical trial data and a revised approach to viral mixtures
    Bart Winters
    Virco BVBA, Mechelen, Belgium
    J Virol Methods 162:101-8. 2009
    ..These results suggest that the updated CCOs provide a relevant tool for estimating the contribution to virological response of individual antiviral drugs in antiretroviral drug combinations as used currently in clinical practice...
  4. ncbi A synthetic HIV-1 subtype C backbone generates comparable PR and RT resistance profiles to a subtype B backbone in a recombinant virus assay
    David Nauwelaers
    Virco BVBA, Beerse, Belgium
    PLoS ONE 6:e19643. 2011
    ....
  5. ncbi The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine
    Michael Sproat
    St Stephens Centre, Chelsea and Westminster Healthcare NHS Trust, London, UK
    Antivir Ther 10:357-61. 2005
    ..05). CONCLUSIONS: While the M184V did increase the fold resistance of HIV to ddl, these changes appeared to be lower than the clinically relevant threshold for phenotypic resistance for this drug...
  6. ncbi Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study)
    Isabelle Pellegrin
    Department of Virology, Bordeaux University Hospital, Bordeaux, France
    Antivir Ther 13:271-9. 2008
    ....